Clariant to Showcase Pharma Polymers and Packaging Solutions at CPhI Worldwide 2015
Exhibits include controlled atmosphere packaging for protection against moisture and oxygen, as well as specialty polymers and active ingredients for healthcare applications, among others.
Clariant announced that it will be at CPhI Worldwide 2015 to showcase its product offerings for the pharmaceutical market. Three business groups from the company will exhibit in Hall 7, Booth 7F28.
- Business Unit Industrial & Consumer Specialties will present innovative, sustainable and trend-based products to support the changing needs of the pharmaceutical market. High-purity ingredients include Polyglykol universally applicable pharmaceutical polymers, and a complete range of Macrogols with various molecular weights, all of them supported by CEP certification and DMF.
- Clariant Healthcare Packaging manufactures controlled atmosphere packaging that helps to protect healthcare products from humidity and oxygen. Its portfolio includes industry-leading desiccant canisters and packets; tubes and desiccant stoppers; Tubairless, an innovative airless packaging system for protecting and dispensing sensitive pharmaceutical semi-solids and creams; EQ-Can and EQ-Pak humidity regulators; and more.
- Clariant Healthcare Polymer Solutions will featuring the MEVOPUR and the REMAFIN-EP brands of color and performance master batches and compounds developed specifically for the medical device and pharmaceutical packaging sector, including new UV-blocking protection for transparent packaging, improved resistance to e-beam, gamma, X-ray sterilization, and new anti-static and anti-blocking functionality for pharmaceutical packaging films. The REMAFIN-EP range of white master batches for pharmaceutical packaging has been extended with increased regulatory support with test documentation for USP661.
Source: Clariant, Booth 7F28
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
